Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The first indications for a role of JAM-A in epithelial barrier formation in vivo came from observations in patients suffering from intestinal inflammatory disorders such as Crohns disease (CD) or ulcerative colitis (UC), which represent the two major forms of IBD (Vetrano et al., 2008)
Both compounds remain widely available through research-grade peptide suppliers operating under 'research use only, not for human consumption' labeling
370 The Phase 0 clinical study (NCT03020017) in eight patients with GBM showed that NU-0129 could pass through the BBB and accumulate in tumors, reducing the abundance of BCL2L12 protein and demonstrating its potential as an innovative therapy for GBM
Not authorised for human consumption or therapeutic use
US$ 29.10
US$ 29.66
US$ 26.72
US$ 25.44
